All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Navigating International Pharmacovigilance

June 2, 2021
By Judith M. Sills, PharmD
Eric Caugant
News
Article
Pharmaceutical TechnologyPharmaceutical Technology, June 2021 Issue
Volume 45
Issue 6

International pharmacovigilance for biotechs brings about a particular set of challenges, especially for small companies, which face the same rigour as large pharma companies.

fotogestoeber - Stock.adobe.com

fotogestoeber - Stock.adobe.com

As biotechs grow in market prominence, the reality is dawning that their pharmacovigilance (PV) obligations are equivalent to those of pharma companies several times their size. For young, ambitious, product-oriented companies, such demands could be a barrier to market success, unless they devise optimum strategies for fulfilling the differing safety demands of respective regulators.

Companies with ambitions for Europe and the United States tend to favour filing in the US first. On top of the US market’s vast size, it benefits from being a single country governed by one main agency—the US Food and Drug Administration (FDA). In Europe, marketing authorization can take much longer because beyond the central European Medicines Agency (EMA) each European Union (EU) member state has its own unique requirements to navigate.

Editor’s Note: This article was published in Pharmaceutical Technology Europe’s June 2021 print issue.

Taking the US and EU as key territories, the diverse PV requirements highlighted in the following give a flavour of just what’s involved and where biotechs are likely to need help.

Pre-marketing expectations

Although in the pre-marketing stage of development, most PV requirements are harmonized across the European and US markets, there are some small, noteworthy variations—for instance FDA’s particular requirements around causality assessment, affecting what’s submitted in the two regions.

Even at a central level, EMA submissions have a different look and format to US dossiers, so they require different handling. For instance, the Summary of Product Characteristics (SmPC) and labelling in relation to side effects are not presented in the same way in Europe.

Differences exist too between the risk management approaches—FDA’s Risk Evaluation and Mitigation Strategies (REMS) versus EMA’s Risk Management Plan (RMP)—and one cannot be substituted for the other. Failure to factor in these differences could present an issue at the time of filing. In addition, national EU-specific requirements may be requested in certain countries, on top of the RMP EU requirements, even for centralized procedures.

To successfully and efficiently navigate the differences between regions, biotechs must set out a clear strategy and timeline for how they will file to their target markets, and plan for multiple markets concurrently (it could take a long time to prepare for EMA’s diverse requirements)—and those of each EU country beyond that, plus the United Kingdom, which now sits outside of the EU/EMA.

It isn’t just European information and formatting requirements that differ and are more involved than in the US. Standard operating procedures (SOPs)/process requirements can be more complex in Europe too. Although, during the pandemic, ‘crisis mode’ enabled emergency acceleration of these processes to expedite the marketing authorization of vital products such as the US-originating Moderna vaccine for use in European markets. This approval was ‘conditional’, and such measures are temporary and cannot be expected going forward.

Post-marketing

The post-marketing regulatory environment is highly regulated and inspection driven, and it is here that biotechs are likely to find the greatest challenges in managing their PV obligations. In post-marketing, the differences between US and European requirements are starker than for pre-marketing.

Europe overhauled its post-marketing PV requirements a couple of decades ago, making these very clear and prescriptive. For post-marketing safety studies, for instance, it has broken down the requirements for interventional versus non-interventional studies and what needs to be reported—or left out—for each. In the US, equivalent post-marketing safety requirements are much older and leave much to interpretation, so companies tend to tread a more cautious path.

Where Europe is content with a final study report, in the US companies still file expedited single case reports; in the EU, expedited reporting is required for Individual Case Safety Reports (ICSRs) for post-marketing safety studies. If studies are used to support a product claim, and the right data have not been collected in the right way for the given market, this could pose problems. So, the different requirements must be well understood and designed into post-marketing and market research studies.

Acquiring the right skillsets

Although biotechs may lead the way with product expertise, this is not typically matched in understanding and expertise in PV requirements and process rigour. To mitigate safety compliance-related risk, they need to establish both the right knowledge and experience, plus skills in writing SOPs and setting up PV systems which, in Europe, must be in place from the time of marketing authorization application (MAA) filing.

Relying on a third-party safety services provider to take on this burden without in-house oversight is not recommended—not least because the marketing authorization holder (MAH) retains ultimate responsibility for PV compliance. Irrespective of the biotech’s size and scale, then, it will need to bring in someone experienced who understands PV and can keep a check on vendor quality.

In Europe, a nominated qualified person responsible for PV (QPPV) is personally responsible for the safety of the human pharmaceutical products marketed by that company in the EU. There will need to be a designated person inside each region, too: so, a US company with European marketing authorization must have a named QPPV based in Europe; and potentially also at a country-level (in France and Spain this is a regulatory requirement).

Establishing remits and responsibility

Where biotechs have entered into distribution relationships with other MAHs, there will be additional considerations—such as who will coordinate and be responsible for the PV requirements in a given market and how this will be written in any contracts. The MAH in the local country always is ultimately responsible for meeting PV requirements in that country. There is also the decision of who will be the global PV database holder (usually the company that developed the product and secured approval).

PV capabilities shouldn’t stand still, either. Biotechs will need to keep pace with both changes to regulatory requirements across all markets globally, and evolving channels and technologies when tracking safety signals; companies have an obligation to monitor and filter web/social media forums for potentially important real-world safety information, where digital media is company-sponsored.

Meanwhile, the increase in combination treatments involving drugs and devices could trigger new rules clarifying how responsibility for adverse drug reactions is apportioned, another situation that needs to be tracked. Establishing an appropriate PV budget will be essential for any biotech navigating all of this international complexity.

About the Authors

Judith M. Sills, PharmD, and Eric Caugant, are both nonexecutive directors and advisors to Arriello—a provider of risk management and compliance services to the Life Sciences industry.

Article Details

Pharmaceutical Technology Europe
Vol. 33, No. 6
June 2021
Pages: 39–40

Citation

When referring to this article, please cite it as J.M. Sills and E. Caugant, “Navigating International Pharmacovigilance,” Pharmaceutical Technology Europe 33 (6) 2021.

Download Issue PDF
Articles in this issue

Ipopba/Stock.adobe.com – Conceptual image of scientist holding up a test tube with imagery of dna, an atom, and molecules surrounding it to illustrate the notion of "new" or "emerging" therapeutic/scientific concepts for drug development.
New Biotherapies Push Technological Innovation Forward
Using Quality by Design to Develop Fixed-Dose Combination Tablets
Using Quality by Design to Develop Fixed-Dose Combination Tablets
Assessing Risk and Production of Potent Substances; image: cassis - stock.adobe.com
Assessing Risk and Production of Potent Substances
Moving Beyond Particle Size Control
Moving Beyond Particle Size Control
cleaning equipment
Cleaning Continuous Manufacturing Equipment
robotic syringe filling
Considering Robotics for Drug Compounding
Considerations for Cleaning Biopharmaceutical Process Equipment
Navigating International Pharmacovigilance
Navigating International Pharmacovigilance
BANKRX - STOCK.ADOBE.COM
Prioritizing Cleaning Validation
Developing a Method for Success through Partnerships
Developing a Method for Success through Partnerships
W.SCOTT MCGILL - STOCK.ADOBE.COM
Pandemic Highlights Need for Advanced Pharma Manufacturing
karramba production - stock.adobe.com
A “We are the World” Vaccination Effort?
From the Chairman: Technology Advances Foster New Therapies
Leigh Prather - stock.adobe.com
The Facts About Filing Drug Applications
Semi-Preparative Affinity Column
Semi-Preparative Affinity Column
Recent Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Related Content

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New CBER Director Appointed

Susan Haigney
May 7th 2025
Article

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


n-nitrosodimethylamine molecular structure, 3d model molecule, n-nitrosamines, structural chemical formula view from a microscope | Image Credit: © Сергей Шиманович - stock.adobe.com

Strategies for Mitigating Nitrosamine Risk

Susan Haigney
May 7th 2025
Article

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines.


White House | Image Credit: © Zack Frank - stock.adobe.com

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

Patrick Lavery
May 7th 2025
Article

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

Related Content

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New CBER Director Appointed

Susan Haigney
May 7th 2025
Article

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


n-nitrosodimethylamine molecular structure, 3d model molecule, n-nitrosamines, structural chemical formula view from a microscope | Image Credit: © Сергей Шиманович - stock.adobe.com

Strategies for Mitigating Nitrosamine Risk

Susan Haigney
May 7th 2025
Article

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines.


White House | Image Credit: © Zack Frank - stock.adobe.com

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

Patrick Lavery
May 7th 2025
Article

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.